三种不同植骨方式治疗单节段腰椎结核的疗效分析:一项单中心回顾性队列研究

注册号:

Registration number:

ChiCTR2000030736 

最近更新日期:

Date of Last Refreshed on:

2020-03-12 23:16:29 

注册时间:

Date of Registration:

2020-03-12 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

三种不同植骨方式治疗单节段腰椎结核的疗效分析:一项单中心回顾性队列研究

Public title:

Comparison of three different bone graft methods for single segment lumbar tuberculosis: a retrospective single-center cohort study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

非结构性植骨与结构性植骨治疗脊柱结核的手术疗效对比

Scientific title:

Comparison of the curative effect between non-structural and structural bone graft in the surgical treatment of spinal tuberculosis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

杜兴 

研究负责人:

欧云生 

Applicant:

Xing Du 

Study leader:

Yunsheng Ou 

申请注册联系人电话:

Applicant telephone:

+86 15683738702

研究负责人电话:

Study leader's
telephone:

+86 18696669699

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

duxing92@yeah.net

研究负责人电子邮件:

Study leader's E-mail:

ouyunsheng3001@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市渝中区袁家岗友谊路1号

研究负责人通讯地址:

重庆市渝中区袁家岗友谊路1号

Applicant address:

1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing, China

Study leader's address:

1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

重庆医科大学附属第一医院骨科

Applicant's institution:

Department of Orthopedics, the First Affiliated Hospital of Chongqing Medical University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2017-067

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

重庆医科大学附属第一医院伦理委员会

Name of the ethic committee:

The Ethics Committee of the First Affiliated Hospital of Chongqing Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2017-06-07 00:00:00

伦理委员会联系人:

重庆医科大学附属第一医院伦理委员会

Contact Name of the ethic committee:

The Ethics Committee of the First Affiliated Hospital of Chongqing Medical University

伦理委员会联系地址:

重庆市渝中区袁家岗友谊路1号

Contact Address of the ethic committee:

1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

重庆医科大学附属第一医院骨科

Primary sponsor:

Department of Orthopedics, the First Affiliated Hospital of Chongqing Medical University

研究实施负责(组长)单位地址:

重庆市渝中区袁家岗友谊路1号

Primary sponsor's address:

1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属第一医院

具体地址:

渝中区袁家岗友谊路1号

Institution
hospital:

The First Affiliated Hospital of Chongqing Medical University

Address:

1 Youyi Road, Yuanjiagang, Yuzhong District

经费或物资来源:

没有相关基金支持

Source(s) of funding:

This work was not supported by any sources of funding.

研究疾病:

脊柱结核  

Target disease:

spinal tuberculosis

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

比较一期后路病灶清除髂骨植骨、钛网植骨与颗粒植骨治疗单节段腰椎结核的临床疗效。  

Objectives of Study:

To compare the clinical efficacy of one stage posterior debridement with iliac bone graft, titanium mesh bone graft or granular bone graft in the surgical treatment of single segment lumbar tuberculosis.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

(1)合并其他节段脊柱结核;
(2)既往脊柱手术史;
(3)活动性肺结核、恶性肿瘤等。

Exclusion criteria:

(1) Combined with other segmental spinal tuberculosis;
(2) Previous history of spinal surgery;
(3) Active pulmonary tuberculosis, malignant tumor, etc.;

研究实施时间:

Study execute time:

From 2020-04-01 00:00:00 To 2021-04-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-04-01 00:00:00 To 2020-06-30 00:00:00

干预措施:

Interventions:

组别:

髂骨植骨组

样本量:

20

Group:

Group 1

Sample size:

干预措施:

采用髂骨植骨

干预措施代码:

Intervention:

Undergoing iliac bone graft

Intervention code:

组别:

钛网植骨组

样本量:

20

Group:

Group 2

Sample size:

干预措施:

采用钛网植骨

干预措施代码:

Intervention:

Undergoing titanium mesh bone graft

Intervention code:

组别:

颗粒植骨组

样本量:

20

Group:

Group 3

Sample size:

干预措施:

采用颗粒植骨

干预措施代码:

Intervention:

Undergoing granular bone graft

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Chongqing Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

手术时间

指标类型:

次要指标

Outcome:

Operative time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术中出血量

指标类型:

次要指标

Outcome:

Operative blood loss

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院时间

指标类型:

次要指标

Outcome:

Hospital stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛视觉模拟评分

指标类型:

主要指标

Outcome:

visual analogue score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

红细胞沉降率

指标类型:

主要指标

Outcome:

erythrocyte sedimentation rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

C反应蛋白

指标类型:

主要指标

Outcome:

C reactive protein

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

局部Cobb角

指标类型:

主要指标

Outcome:

Cobb angle

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

植骨融合时间

指标类型:

主要指标

Outcome:

bone graft fusion time

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

并发症

指标类型:

副作用指标

Outcome:

Complication

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

神经功能分级

指标类型:

主要指标

Outcome:

ASIA grade

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究为回顾性队列研究,不涉及随机分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

This study is a retrospective cohort study and does not involve random grouping.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

N/A

Blinding:

N/A

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

暂未定

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not yet decided

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

暂未定

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Not yet decided

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-03-12 23:16:29